Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QAX576 in pulmonary fibrosis secondary to systemic sclerosis
NCT00581997Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2007
- Primary completion
- Apr 2009
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of dectrekumab in pulmonary fibrosis (PF), systemic sclerosis (SSc), sponsored by Novartis. Started Dec 2007; status: terminated.
02
Drugs
dectrekumab
03
Conditions
pulmonary fibrosis (PF)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT00581997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00581997.